-transparent.png){kind=logo}
Subcutaneously administered implant-D containing 40 mg of Norethindrone acetate in a single silastic implant was offered to 79 subjects who desired spacing of their family. The effect of constant release of steroid from this device on metabolic and endocrine functions was studied. Each subject in the pretreatment state served as her own control. The device was removed at 8 months initially and subsequently at 5-6 months. The clinical acceptability of this method was fairly high. The results reported in this study show that Norethindrone acetate administered in this way did not cause any adverse reactions on endocrine and metabolic functions as gauged by the parameters analysed.
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
February 1982,
Acta endocrinologica,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
January 1977,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
December 1978,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
October 1979,
American journal of obstetrics and gynecology,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
February 1978,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
April 1977,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
April 1978,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
September 2021,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
October 1977,
Contraception,
S M Shahani, and
P P Kulkarni, and
P A Bhate, and
K L Patel
June 2007,
The Journal of clinical endocrinology and metabolism,
